Molecular pathways: Cbl proteins in tumorigenesis and antitumor immunity - Opportunities for cancer treatment

Clinical Cancer Research

Volumn 21, Issue 8, 2015, Pages 1789-1794

  Liyasova, Mariya S ^a   Ke, Ma ^a   Lipkowitz, Stanley ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; CD135 ANTIGEN; CD28 ANTIGEN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; STAT5 PROTEIN; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VAV PROTEIN;

ADAPTIVE IMMUNITY; ARTICLE; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CATALYSIS; CD8+ T LYMPHOCYTE; CELL MIGRATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; HUMAN; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; UBIQUITINATION; ANIMAL; CELL TRANSFORMATION; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; TRANSLATIONAL RESEARCH;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-CBL; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84927669840     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2490     Document Type: Article

References (66)

1. Tsygankov A, editor. Cbl proteins. New York: Nova Science Publishers; 2008.
2. Nau MM, Lipkowitz S. Welcome to the family: Cbl-family gene organization, overview of structure and functions of Cbl-related proteins in various taxonomical groups. In:Tsygankov AY, editor. Cbl proteins. New York: Nova Science Publishers; 2008. p. 3-25.
3. Schmidt MH, Dikic I. The Cbl interactome and its functions. Nat Rev Mol Cell Biol 2005;6:907-19.
4. Rao N, Dodge I, Band H. The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J Leukoc Biol 2002;71:753-63.
5. Thien CB, Langdon WY. Cbl:many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2001;2:294-307.
6. Tsygankov AY, Teckchandani AM, Feshchenko EA, Swaminathan G. Beyond the RING: CBL proteins as multivalent adapters. Oncogene 2001;20:6382-402.
7. Weissman AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2001;2:169-78.
8. Dou H, Buetow L, Hock A, Sibbet GJ, Vousden KH, Huang DT. Structural basis for autoinhibition of and phosphorylation-dependent activation of c-Cbl. Nat Struct Mol Biol 2012;19:184-92.
9. Kassenbrock CK, Anderson SM. Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations. J Biol Chem 2004;279:28017-27.
10. Kobashigawa Y, Tomitaka A, Kumeta H, Noda NN, Yamaguchi M, Inagaki F. Autoinhibition and phosphorylation-induced activationmechanisms of human cancer and autoimmune disease-related E3 protein Cbl-b. Proc Natl Acad Sci U S A 2011;108:20579-84.
11. Ryan PE, Sivadasan-Nair N, Nau MM, Nicholas S, Lipkowitz S. The Nterminus of Cbl-c regulates ubiquitin ligase activity by modulating affinity for the ubiquitin conjugating enzyme. J Biol Chem 2010;285:23687-98.
12. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999;4: 1029-40.
13. Lill NL, Douillard P, Awwad RA, Ota S, Lupher ML Jr, Miyake S, et al. The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor. J Biol Chem 2000;275:367-77.
14. Lupher ML Jr, Reedquist KA, Miyake S, Langdon WY, Band H. A novel phosphotyrosine-binding domain in the N-terminal transforming region of Cbl interacts directly and selectively with ZAP-70 in T cells. J Biol Chem 1996;271:24063-8.
15. Scott RP, Eketjall S, Aineskog H, Ibanez CF. Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase. J Biol Chem 2005; 280:13442-9.
16. WatermanH, KatzM, Rubin C, Shtiegman K, Lavi S, Elson A, et al. Amutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J 2002;21:303-13.
17. Kales SC, Ryan PE, Lipkowitz S. Cbl exposes its RING finger. Nat StructMol Biol 2012;19:131-3.
18. Ma K, Kales SC,Nau MM, Lipkowitz S. Cbl as amaster regulator of receptor tyrosine kinase traf ficking. In:Yarden Y, Tarcic G, editors. Vesicle trafficking in cancer. New York: Springer; 2013. p. 219-44.
19. Dombrosky-Ferlan PM, Corey SJ. Yeast two-hybrid in vivo association of the Src kinase Lyn with the proto-oncogene product Cbl but not with the p85 subunit of PI 3-kinase. Oncogene 1997;14:2019-24.
20. Ueno H, Sasaki K, Honda H, Nakamoto T, Yamagata T, Miyagawa K, et al. c-Cbl is tyrosine-phosphorylated by interleukin-4 and enhances mitogenic and survival signals of interleukin-4 receptor by linking with the phosphatidylinositol 3′-kinase pathway. Blood 1998;91:46-53.
21. Langdon WY, Hartley JW, Klinken SP, Ruscetti SK, Morse HC III. v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early Blineage lymphomas. Proc Natl Acad Sci U S A 1989;86:1168-72.
22. Bonita DP, Miyake S, Lupher MLJ, Langdon WY, Band H. Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity. Mol Cell Biol 1997; 17:4597-610.
23. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998;12:3663-74.
24. Bisson SA, Ujack EE, Robbins SM. Isolation and characterization of a novel, transforming allele of the c-Cbl proto-oncogene from a murine macrophage cell line. Oncogene 2002;21:3677-87.
25. Blake TJ, Shapiro M, Morse HC III, Langdon WY. The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipperlike motif. Oncogene 1991;6:653-7.
26. Rathinam C, Thien CB, Flavell RA, Langdon WY. Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling. Cancer Cell 2010;18:341-52.
27. Naramura M, Nandwani N, Gu H, Band V, Band H. Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells. Proc Natl Acad Sci U S A 2010;107:16274-9.
28. Thien CB, Langdon WY. Tyrosine kinase activity of the EGF receptor is enhanced by the expression of oncogenic 70Z-Cbl. Oncogene 1997;15: 2909-19.
29. Kales SC, Ryan PE, Nau MM, Lipkowitz S. Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Res 2010;70:4789-94.
30. COSMIC: catalogue of somatic mutations in cancer [database on the Internet]. Cambridge (UK): Wellcome Trust Sanger Institute, Genome Research Limited. c2004 - [cited 2014 Oct 19]. Available from: http://www.sanger.ac.uk/genetics/CGP/cosmic/
31. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009;113:6182-92.
32. Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009;114:1859-63.
33. Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B, et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res 2009;15:2238-47.
34. Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009;460:904-8.
35. Abbas S, Rotmans G, Lowenberg B, Valk PJ. Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias. Haematologica 2008;93:1595-7.
36. Beer PA, Delhommeau F, Lecouedic JP, Dawson MA, Chen E, Bareford D, et al. Two routes to leukemic transformation following a JAK2 mutationpositive myeloproliferative neoplasm. Blood 2010;115:2891-900.
37. Caligiuri MA, Briesewitz R, Yu J, Wang L, WeiM, Arnoczky KJ, et al. Novel c-CBL and CBL-B ubiquitin ligase mutations in human acute myeloid leukemia. Blood 2007;110:1022-4.
38. Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, Szpurka H, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008;68:10349-57.
39. Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009; 27:6109-16.
40. Muramatsu H, Makishima H, Jankowska AM, Cazzolli H, O'Keefe C, Yoshida N, et al. Mutations of E3 ubiquitin ligase Cbl family members but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood 2010;115:1969-75.
41. Sargin B, Choudhary C, Crosetto N, Schmidt MH, Grundler R, Rensinghoff M, et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 2007;110:1004-12.
42. Thien CB, Walker F, Langdon WY. RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation. Mol Cell 2001;7:355-65.
43. Bandi SR, Brandts C, Rensinghoff M, Grundler R, Tickenbrock L, Kohler G, et al. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. Blood 2009;114:4197-208.
44. Griffiths EK, Sanchez O, Mill P, Krawczyk C, Hojilla CV, Rubin E, et al. Cbl- 3-deficient mice exhibit normal epithelial development. Mol Cell Biol 2003;23:7708-18.
45. KeaneMM, Ettenberg SA, Nau MM, Banerjee P, Cuello M, Penninger J, et al. cbl-3: a new mammalian cbl family protein. Oncogene 1999;18:3365-75.
46. Kim M, Tezuka T, Suziki Y, Sugano S, Hirai M, Yamamoto T. Molecular cloning and characterization of a novel cbl-family gene, cbl-c. Gene 1999; 239:145-54.
47. Nicholson L, Knight T, Matheson E, Minto L, Case M, Sanichar M, et al. Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2012;51:250-6.
48. McKeller MR, Robetorye RS, Dahia PL, Aguiar RC. Integrity of the CBL gene in mature B-cell malignancies. Blood 2009;114:4321-2.
49. cBio Portal for Cancer Genomics [database on the Internet]. Bethesda (MD): The Cancer Genome Atlas Program Office. c2010 - cited 2014 Oct 19]. Available from: http://www.cbioportal.org/public-portal/index.do
50. Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, et al. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS ONE 2010;5:e8972.
51. Grunwald MR, Levis MJ. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol 2013;97:683-94.
52. Taylor SJ, Dagger SA, Thien CB, Wikstrom ME, Langdon WY. Flt3 inhibitor AC220 is a potent therapy in a mouse model ofmyeloproliferative disease driven by enhanced wild-type Flt3 signaling. Blood 2012;120:4049-57.
53. Kumar EA, Charvet CD, Lokesh GL, Natarajan A. High-throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)-protein tyrosine kinase interactions. Anal Biochem 2011;411:254-60.
54. Kumar EA, Yuan Z, Palermo NY, Dong L, Ahmad G, Lokesh GL, et al. Peptide truncation leads to a twist and an unusual increase in affinity for casitas B-lineage lymphoma tyrosine kinase binding domain. J Med Chem 2012;55:3583-7.
55. Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos- Santos A, et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 2000;403:211-6.
56. Chiang YJ, Kole HK, Brown K, NaramuraM, Fukuhara S, Hu RJ, et al. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 2000;403: 216-20.
57. Murphy MA, Schnall RG, Venter DJ, Barnett L, Bertoncello I, Thien CBF, et al. Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-cbl-deficient mice. Mol Cell Biol 1998;18:4872-82.
58. NaramuraM, Kole HK, Hu RJ, Gu H. Altered thymic positive selection and intracellular signals in Cbl-de ficient mice. Proc Natl Acad Sci U S A 1998; 95:15547-52.
59. Fang D, Liu YC. Proteolysis-independent regulation of PI3K by Cbl-bmediated ubiquitination in T cells. Nat Immunol 2001;2:870-5.
60. Fang D, Wang HY, Fang N, Altman Y, Elly C, Liu YC. Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells. J Biol Chem 2001;276:4872-8.
61. Chiang JY, Jang IK, Hodes R, Gu H. Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. J Clin Invest 2007;117: 1029-36.
62. Loeser S, Loser K, Bijker MS, Rangachari M, van der Burg SH, Wada T, et al. Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med 2007;204:879-91.
63. Paolino M, Thien CB,Gruber T, Hinterleitner R, Baier G, Langdon WY, et al. Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions. J Immunol 2011;186:2138-47.
64. PaolinoM, Choidas A,Wallner S, Pranjic B, Uribesalgo I, Loeser S, et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 2014;507:508-12.
65. Valverde P. Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and downregulation. Biochem Biophys Res Commun 2005;333:180-5.
66. Stromnes IM, Blattman JN, Tan X, Jeevanjee S, Gu H, Greenberg PD. Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice. J Clin Invest 2010;120: 3722-34.